secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001664710-23-000048
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Q2 net loss $37.5M, cash $322M; plans KER-065 Phase 1 in DMD for Q1 2024
------------------------------------------------------------------------------

- Net loss of $37.5M in Q2 2023 vs $27.3M in Q2 2022, driven by increased R&D spend.
- R&D expenses $32.5M (+$9.3M YoY) on pipeline advancement and manufacturing.
- Cash and equivalents $322.0M as of June 30, 2023; expects runway into Q4 2025.
- Phase 2 TROPOS trial of KER-012 in PAH cleared by FDA; webcast on trial design Aug 8.
- KER-065 for Duchenne muscular dystrophy to start Phase 1 in healthy volunteers Q1 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/0001664710-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000048/kros-20230807.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer